Researchers at The University of Texas MD Anderson Cancer Center and The University of Texas at Austin have identified specific blood-based genomic biomarkers that distinguish inflammatory breast cancer from other subtypes, providing a new and less invasive method for early diagnosis, disease progression monitoring and treatment development for patients with this aggressive disease.
More...